Complarate

Phase 1Biologic

AAO GENERIUM

Complarate is one of 4 biologic programs targeting Tocilizumab. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TocilizumabActive, not recruiting

TocilizumabPhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Tocilizumab

#DrugCompanyPhaseTrials

Actemra

CCelltrion

Approved

36 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 3

Xeljanz

PPrism Pharmaceuticals

Phase 2

1 4

Complarate

AAO GENERIUM

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tocilizumab2 trials

A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers

Completed·AAO GENERIUM·Phase 1·NCT06481202·43 enrolled

A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers

Active, not recruiting·AAO GENERIUM·Phase 1·NCT06488521·256 enrolled

Rheumatoid Arthritis1 trial

Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis

Completed·AAO GENERIUM·Phase 3·NCT06475508·465 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Complarate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Complarate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Complarate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AO GENERIUM company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: AAO GENERIUM

Complarate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tocilizumab2 trials

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News